Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Haig P. Bozigian sold 22,500 shares of the company’s stock in a transaction on Friday, August 4th. The shares were sold at an average price of $50.00, for a total value of $1,125,000.00. Following the sale, the insider now owns 154,601 shares of the company’s stock, valued at approximately $7,730,050. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Neurocrine Biosciences, Inc. (NBIX) traded down 0.28% during mid-day trading on Tuesday, reaching $53.65. The company’s stock had a trading volume of 1,058,024 shares. The company’s market capitalization is $4.73 billion. Neurocrine Biosciences, Inc. has a one year low of $37.35 and a one year high of $55.38. The stock has a 50-day moving average price of $47.37 and a 200-day moving average price of $46.32.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Thursday, August 3rd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by $0.01. The business had revenue of $6.34 million during the quarter, compared to the consensus estimate of $0.61 million. During the same quarter last year, the firm posted ($0.46) earnings per share. Equities research analysts forecast that Neurocrine Biosciences, Inc. will post ($2.45) EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/08/08/insider-selling-neurocrine-biosciences-inc-nasdaqnbix-insider-sells-22500-shares-of-stock.html.

A number of hedge funds have recently made changes to their positions in NBIX. Dimensional Fund Advisors LP raised its stake in shares of Neurocrine Biosciences by 2.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 165,953 shares of the company’s stock worth $6,422,000 after buying an additional 4,428 shares during the last quarter. Teachers Advisors LLC raised its stake in Neurocrine Biosciences by 6.3% in the fourth quarter. Teachers Advisors LLC now owns 78,287 shares of the company’s stock worth $3,030,000 after buying an additional 4,668 shares in the last quarter. Capstone Asset Management Co. bought a new stake in Neurocrine Biosciences during the first quarter worth $214,000. Quantitative Systematic Strategies LLC bought a new stake in Neurocrine Biosciences during the first quarter worth $261,000. Finally, Columbus Circle Investors raised its stake in Neurocrine Biosciences by 33.3% in the first quarter. Columbus Circle Investors now owns 207,699 shares of the company’s stock worth $8,993,000 after buying an additional 51,872 shares in the last quarter. 96.48% of the stock is currently owned by institutional investors.

A number of analysts recently commented on NBIX shares. Bank of America Corporation started coverage on Neurocrine Biosciences in a research report on Friday, May 5th. They set a “buy” rating and a $70.00 price objective for the company. BidaskClub upgraded Neurocrine Biosciences from a “sell” rating to a “hold” rating in a research report on Wednesday, June 21st. Jefferies Group LLC upped their price objective on Neurocrine Biosciences from $59.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, April 12th. Leerink Swann reduced their price objective on Neurocrine Biosciences from $68.00 to $66.00 and set an “outperform” rating for the company in a research report on Thursday, May 25th. Finally, Oppenheimer Holdings, Inc. reiterated an “outperform” rating and set a $70.00 price objective on shares of Neurocrine Biosciences in a research report on Wednesday, July 5th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and sixteen have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $68.25.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Insider Buying and Selling by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.